Table 1.
Characteristics of participants.
| Use of hormone therapy | |||
|---|---|---|---|
| Oral E2 (n=93) | Oral CEE (n=48) | None (n=141) | |
| Age, years (mean, SD) | 63.8 (10.6) | 65.3 (8.9) | 64.0 (10.0) |
| White, n (%) | 83 (89.3%) | 48 (100.0%) | 130 (92.2%) |
| Good to excellent self-reported health status, n (%) | 76 (82.6%) | 37 (80.4%) | 121 (88.3%) |
| BMI, kg/m2 (mean, SD) | 28.6 (6.1) | 28.0 (5.6) | 29.9 (7.6) |
| Current smoking, n (%) | 8 (8.6%) | 1 (2.1%) | 14 (9.9%) |
| Diabetes, n (%) | 4 (4.3%) | 4 (8.3%) | 19 (13.5%) |
| Hyperlipidemia, n (%) | 9 (9.7%) | 4 (8.3%) | 25 (17.7%) |
| Total cholesterol, mg/dl (mean, SD) | 212.3 (37.3) | 235.2 (40.0) | 209.2 (40.4) |
| Hypertension, n (%) | 53 (57.0%) | 26 (54.2%) | 77 (54.6%) |
| SBP, mmHg (mean, SD) | 132.1 (18.9) | 136.6 (23.6) | 131.4 (17.6) |
| History of cardiovascular disease*, n (%) | 5 (5.4%) | 3 (6.3%) | 11 (7.8%) |
| Statin Use, n (%) | 11 (11.8%) | 8 (16.7%) | 25 (17.7%) |
| Cancer <= 5 years prior, n (%) | 2 (2.2%) | 1 (2.1%) | 2 (1.4%) |
| Factor V Leiden †, n (%) | 7 (10.9%) | 1 (2.1%) | 3 (2.8%) |
| Estrogen daily dose, n (%) | |||
| CEE <0.625mg or E2<1mg | 35 (37.6%) | 9 (18.8%) | |
| CEE 0.625mg or E2 1mg | 51 (54.9%) | 31 (65.6%) | |
| CEE >0.625mg or E2>1mg | 7 (7.5%) | 8 (16.7%) | |
| Progestin (MPA) use, n (%) | 28 (30.1%) | 10 (20.8%) | |
*
defined as a history of myocardial infarction, angina, coronary artery bypass grafting, angioplasty, stroke, carotid endarterectomy, claudication, or peripheral vascular bypass
†
among participants with non-missing FVL status (77%). FVL missing in 35 non-HT users (24.8%), 29 E2 users (31.2%), and 1 CEE user (2.1%).
E2 = estradiol; CEE = conjugated equine estrogen; SBP = systolic blood pressure; MPA = medroxyprogesterone acetate